Insider Selling: Crispr Therapeutics AG (NASDAQ:CRSP) President Sells 50,000 Shares of Stock

Crispr Therapeutics AG (NASDAQ:CRSP) President Rodger Novak sold 50,000 shares of the firm’s stock in a transaction on Wednesday, July 10th. The shares were sold at an average price of $50.00, for a total transaction of $2,500,000.00. Following the sale, the president now owns 848,007 shares in the company, valued at $42,400,350. The sale was disclosed in a document filed with the SEC, which is available through the SEC website.

Rodger Novak also recently made the following trade(s):

  • On Monday, June 10th, Rodger Novak sold 50,000 shares of Crispr Therapeutics stock. The shares were sold at an average price of $45.00, for a total transaction of $2,250,000.00.

CRSP traded down $0.07 during trading on Friday, hitting $49.11. 287,431 shares of the company traded hands, compared to its average volume of 666,346. The company has a market cap of $2.64 billion, a P/E ratio of -14.28 and a beta of 3.11. The stock has a 50-day moving average price of $42.99. Crispr Therapeutics AG has a 1 year low of $22.22 and a 1 year high of $66.26. The company has a debt-to-equity ratio of 0.08, a quick ratio of 15.84 and a current ratio of 15.84.

Crispr Therapeutics (NASDAQ:CRSP) last posted its earnings results on Monday, April 29th. The company reported ($0.93) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.90) by ($0.03). The company had revenue of $0.30 million for the quarter, compared to analysts’ expectations of $1.50 million. Crispr Therapeutics had a negative net margin of 8,839.02% and a negative return on equity of 50.90%. The business’s revenue was down 78.6% on a year-over-year basis. During the same period in the previous year, the business posted ($0.62) earnings per share. Analysts anticipate that Crispr Therapeutics AG will post -3.82 earnings per share for the current fiscal year.

A number of institutional investors and hedge funds have recently bought and sold shares of CRSP. FMR LLC grew its stake in shares of Crispr Therapeutics by 5.7% in the 4th quarter. FMR LLC now owns 315,836 shares of the company’s stock worth $9,024,000 after buying an additional 16,900 shares in the last quarter. Deutsche Bank AG grew its stake in shares of Crispr Therapeutics by 65,962.5% in the 4th quarter. Deutsche Bank AG now owns 5,285 shares of the company’s stock worth $150,000 after buying an additional 5,277 shares in the last quarter. Pearl River Capital LLC purchased a new position in shares of Crispr Therapeutics in the 1st quarter worth $252,000. SHANDA ASSET MANAGEMENT HOLDINGS Ltd purchased a new position in shares of Crispr Therapeutics in the 4th quarter worth $1,662,000. Finally, Two Sigma Advisers LP grew its stake in shares of Crispr Therapeutics by 14.5% in the 4th quarter. Two Sigma Advisers LP now owns 473,100 shares of the company’s stock worth $13,516,000 after buying an additional 60,000 shares in the last quarter. 48.96% of the stock is owned by institutional investors.

Several analysts have recently commented on CRSP shares. BTIG Research raised their price objective on shares of Crispr Therapeutics from $30.00 to $33.00 and gave the company a “buy” rating in a research report on Monday, April 22nd. BidaskClub cut shares of YRC Worldwide from a “buy” rating to a “hold” rating in a research note on Tuesday, April 30th. Needham & Company LLC reaffirmed a “buy” rating and set a $10.00 target price (down from $15.00) on shares of Nabriva Therapeutics in a research note on Wednesday, May 1st. Zacks Investment Research cut shares of EXACT Sciences from a “hold” rating to a “sell” rating in a research note on Tuesday, July 2nd. Finally, Evercore ISI began coverage on shares of Homology Medicines in a research note on Thursday, April 11th. They set an “outperform” rating and a $29.00 target price for the company. Two research analysts have rated the stock with a sell rating, five have assigned a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the company. The company currently has a consensus rating of “Hold” and an average price target of $49.88.

About Crispr Therapeutics

CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for the treatment of serious human diseases using its regularly interspaced short palindromic repeats associated protein-9 (CRISPR/Cas9) gene-editing platform in Switzerland. Its lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from dependent beta thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells.

Featured Article: What is the downside to momentum investing?

Insider Buying and Selling by Quarter for Crispr Therapeutics (NASDAQ:CRSP)

Receive News & Ratings for Crispr Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crispr Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply